[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"focal-vitiligo\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:focal-vitiligo":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":5},"100650088","early-phase-1-efficacy-of-topical-tyrosine-versus-topical-5-fluorouracil-with-fractional-erbium-yag-laser-100650088",false,"NCT07742982","Efficacy of Topical Tyrosine Versus Topical 5-Fluorouracil With Fractional Erbium YAG Laser","Efficacy of Topical Tyrosine Versus Topical 5-Fluorouracil With Fractional Erbium YAG Laser in Focal Vitiligo: A Randomised Clinical Trial","Inclusion Criteria:\n\n\\- Patients with focal vitiligo\n\nExclusion Criteria:\n\n* Pregnancy.\n* Lactation.\n* Patients with segmental vitiligo.\n* Patients with autoimmune disease including thyroiditis.\n* Patients with chronic systemic diseases,such as anemia ,diabetes mellitus, immunosuppression, or chronic infections.\n* Patients with active skin infections.","ALL","18 Years","60 Years",{"count":20,"type":21},40,"ESTIMATED","INTERVENTIONAL",[24],"EARLY_PHASE1","Vitiligo is an autoimmune disorder affecting the skin, specifically targeting pigment-producing melanocytes, leading to noticeable regions of depigmentation characterized by white spots.\n\nIt is a widely prevalent skin disorder globally, affecting males and females almost equally, although it is reported slightly more frequently in females. In more than 60% of patients, the disease begins before the age of 30 and It has an estimated prevalence of roughly 0.2-2% across various populations, with around 0.4% in the European-derived white (EUR) population.",[27],"Focal Vitiligo","RECRUITING","2026-08-07",{"date":31,"type":32},"2026-08-11","ACTUAL",{"date":34,"type":32},"2026-06-01",{"date":36,"type":21},"2027-06-10",{"name":38,"class":39},"Aswan University","OTHER"]